ADXN
Income statement / Annual
Last year (2023), Addex Therapeutics Ltd's total revenue was $1.61 M,
an increase of 13.39% from the previous year.
In 2023, Addex Therapeutics Ltd's net income was -$10.56 M.
See Addex Therapeutics Ltd,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.61 M |
$1.42 M |
$2.92 M |
$3.61 M |
$2.76 M |
$6.04 M |
$499,894.00 |
$17,329.00 |
$40,301.00 |
$85,404.00 |
| Cost of Revenue |
$6.94 M
|
$14.62 M
|
$12.82 M
|
$10.37 M
|
$230,097.00
|
$144,169.00
|
$29,764.00
|
$17,329.00
|
$40,301.00
|
$85,404.00
|
| Gross Profit |
-$5.32 M
|
-$13.20 M
|
-$9.90 M
|
-$6.76 M
|
$2.53 M
|
$5.90 M
|
$470,130.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
-3.3
|
-9.28
|
-3.4
|
-1.87
|
0.92
|
0.98
|
0.94
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.75 M
|
$14.67 M
|
$12.84 M
|
$10.37 M
|
$12.45 M
|
$2.37 M
|
$841,308.00
|
$819,330.00
|
$761,217.00
|
$258,058.00
|
| General & Administrative Expenses |
$7.20 M
|
$7.30 M
|
$5.14 M
|
$5.15 M
|
$4.27 M
|
$4.72 M
|
$2.20 M
|
$1.52 M
|
$1.57 M
|
$1.55 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.20 M
|
$7.30 M
|
$5.14 M
|
$5.15 M
|
$4.27 M
|
$4.72 M
|
$2.20 M
|
$1.52 M
|
$1.57 M
|
$1.55 M
|
| Other Expenses |
$1.94 M
|
-$22,521.00
|
$444,000.00
|
$336,676.00
|
$648,165.00
|
$382,993.00
|
$197,669.00
|
$799,702.00
|
$311,823.00
|
-$9,441.00
|
| Operating Expenses |
$11.89 M
|
$21.94 M
|
$18.42 M
|
$15.86 M
|
$17.37 M
|
$7.47 M
|
$3.24 M
|
$3.14 M
|
$2.64 M
|
$1.80 M
|
| Cost And Expenses |
$11.89 M
|
$21.94 M
|
$18.42 M
|
$15.86 M
|
$17.37 M
|
$7.47 M
|
$3.24 M
|
$3.14 M
|
$2.64 M
|
$1.80 M
|
| Interest Income |
$63,964.00
|
$29,251.00
|
$5,322.00
|
$35,305.00
|
$36,874.00
|
$85,866.00
|
$0.00
|
$27.00
|
$39,860.00
|
$1,586.00
|
| Interest Expense |
$21,607.00
|
$48,897.00
|
$63,012.00
|
$69,502.00
|
$128,518.00
|
$220,173.00
|
$45,350.00
|
$6,924.00
|
$152,210.00
|
$0.00
|
| Depreciation & Amortization |
$305,952.00
|
$323,144.00
|
$347,613.00
|
$378,754.00
|
$333,844.00
|
$2,937.00
|
$15,249.00
|
$25,761.00
|
$25,878.00
|
$110,135.00
|
| EBITDA |
-$10.23 M |
-$20.23 M |
-$14.94 M |
-$12.41 M |
-$14.32 M |
-$1.51 M |
-$3.22 M |
-$3.12 M |
-$2.61 M |
-$1.71 M |
| EBITDA Ratio |
-6.34
|
-14.18
|
-5.2
|
-3.27
|
-5.15
|
-0.24
|
-6.44
|
-179.79
|
-64.89
|
-19.98
|
| Operating Income Ratio |
-6.37
|
-14.43
|
-5.32
|
-3.39
|
-5.37
|
-0.24
|
-6.47
|
-180.6
|
-95.98
|
-21.04
|
| Total Other Income/Expenses Net |
-$274,928.00
|
-$284,006.00
|
$154,003.00
|
-$615,325.00
|
-$176,447.00
|
-$220,173.00
|
-$45,350.00
|
-$19,789.00
|
-$1.56 M
|
$748,346.00
|
| Income Before Tax |
-$10.56 M
|
-$20.80 M
|
-$15.35 M
|
-$12.86 M
|
-$14.78 M
|
-$1.64 M
|
-$3.28 M
|
-$3.15 M
|
-$4.20 M
|
-$1.77 M
|
| Income Before Tax Ratio |
-6.54
|
-14.63
|
-5.26
|
-3.56
|
-5.35
|
-0.27
|
-6.56
|
-181.74
|
-104.32
|
-20.78
|
| Income Tax Expense |
$0.00
|
$123,910.00
|
$116,377.00
|
$207,762.00
|
$429,009.00
|
$1.00
|
$0.00
|
$6,924.00
|
$152,210.00
|
-$21,678.00
|
| Net Income |
-$10.56 M
|
-$20.80 M
|
-$15.35 M
|
-$12.86 M
|
-$14.78 M
|
-$1.64 M
|
-$3.28 M
|
-$3.15 M
|
-$4.20 M
|
-$1.77 M
|
| Net Income Ratio |
-6.54
|
-14.63
|
-5.26
|
-3.56
|
-5.35
|
-0.27
|
-6.56
|
-181.74
|
-104.32
|
-20.78
|
| EPS |
-0.14 |
-0.46 |
-0.45 |
-0.48 |
-0.56 |
-0.0706 |
-0.25 |
-0.28 |
-0.39 |
-0.18 |
| EPS Diluted |
-0.14 |
-0.46 |
-0.45 |
-0.48 |
-0.56 |
-0.0706 |
-0.25 |
-0.28 |
-0.39 |
-0.18 |
| Weighted Average Shares Out |
$74.31 M
|
$45.18 M
|
$34.12 M
|
$26.68 M
|
$26.43 M
|
$23.29 M
|
$12.94 M
|
$11.41 M
|
$10.85 M
|
$9.98 M
|
| Weighted Average Shares Out Diluted |
$74.31 M
|
$45.18 M
|
$34.12 M
|
$26.68 M
|
$26.43 M
|
$23.29 M
|
$12.94 M
|
$11.41 M
|
$10.85 M
|
$9.98 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
